32 results about "Fertility Disorders" patented technology

The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of a subject having or at risk for psychiatric and neurodegenerative diseases, infectious diseases, fertility disorders, osteoporosis, osteoarthritis, and/or cardiovascular diseases. Specifically, the present invention relates to compositions comprising endoxifen for use in the treatment of such disorders or predisposition to such disorders, for use in manufacture of medicaments for treating such disorders, and methods comprising use of such compositions in such treatments.

The present invention relates to processes for production of Very Long Chain Polyunsaturated Fatty Acids (VLC-PUFAs). The present invention also relates to compositions (e.g., nutritional supplements and food products) containing such VLC-PUFAs. In one embodiment, the present invention is directed to methods for biosynthesis and production of the VLC-PUFAs described herein (particularly C28-C38 PUFAs, also referred to herein as supraenes or supraenoics) by the expression, in a production host cell, of the full or partial sequence(s) of Elovl4 DNA/mRNA nucleic acids or ELOVL4 protein sequences encoded thereby, from any species (prokaryotic or eukaryotic) for use in the biosynthesis, production, purification and utilization of VLC-PUFAs in particular by the elongation of C18-C26 saturated fatty acids and PUFAs. The composition of the invention comprises, in various embodiments, a dietary supplement, a food product, a pharmaceutical formulation, a humanized animal milk, an infant formula, a cosmetic item and a biodiesel fuel for example. A pharmaceutical formulation can include, but is not limited to: a drug for treatment of neurodegenerative disease, a retinal disorder, age related maculopathy, a fertility disorder, particularly regarding sperm or testes, or a skin disorder.

An improvement to the method of intrauterine insemination by the administration of luteinizing hormone-releasing hormone antagonists (LHRH antagonists).

Novel benzamide derivatives of formula (I)

wherein W¹, W², R¹ to R¹⁰ and X have the meaning according to the claims, are positive allosteric modulators of the FSH receptor, and can be employed, inter alia, for the treatment of fertility disorders.

Novel dihydropyrazole derivatives of formula (I)

The present invention relates γ-lactam derivatives, in particular for use as medicaments, as well as pharmaceutical formulations containing such γ-lactam derivatives. Said γ-lactam derivatives are useful in the treatment and/or prevention of asthma, hypertension, osteoporosis, sexual dysfunction and fertility disorders.

The present invention relates to hydrazide derivatives of Formula I notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such hydrazide derivatives. Said hydrazide derivatives are useful in the treatment of preterm labor, dysmenorrhea, fertility disorders, asthma, hypertension, undesired blood clotting, preelampsia, eclampsia, an eosinophil disorder, undesired bone loss, renal dysfunction, an immune deficiency disorder, ichthyosis, elevated intraocular pressure, infertility, sexual dysfunction, gastric ulcers and inflammatory disorders.

The invention provides IL-1 inhibitors, methods and uses thereof for retaining ovarian follicle reserve in a mammalian subject, treating infertility and improving responsiveness and sensitivity to COH. The invention further provides methods for improving oocyte quality and/or survival, specifically for IVF, and kits for combining COH treatment with the sensitizing IL-inhibitors of the invention.

A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural levelS thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing-posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist/day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralizing the negative effects of HCG.

The invention discloses application of nicotinic acid in preparation of a medicine for treating and/or preventing fertility disorder of obese women, and belongs to the technical field of medicines. According to the invention, through in-vivo supplement or in-vitro addition of nicotinic acid, fertility of obese women can be effectively improved, abnormal assembly proportion and oxidative stress level of meiosis devices in mature ova are reduced, and early embryos after fertilization are promoted to develop to blastocyst stage; the method is of great significance to prevention and/or treatment of female infertility caused by obesity. Nicotinic acid is an important endogenous substance in an organism, is very stable in structure and property, low in price and easy to obtain, and can play a role when being supplemented in vivo or added in vitro, so that the nicotinic acid is very high in practicability when being used as a medicine or a biological preparation.

The present invention relates to deuterated thiazolidinone analogues as agonists for follicle stimulating hormone receptor and their use for treating fertility disorders.

Recombinant human luteinizing hormone (LH) having a specific bioactivity of from 20,522 to 31,229 IU/mg and obtainable from a process for the purification of recombinant LH from a sample of crude recombinant LH in the supernatant of CHO cells which comprises the combined use of ion-exchange chromatography and reverse phase HPLC. The ion-exchange chromatography and the reverse phase HPLC are performed twice and the final use of a gel permeation column allows the purification from any residual traces of contaminants. The recombinant LH can be formulated into a pharmaceutical composition and used for treating a fertility disorder.

The invention relates to preparation and application of an animal model with broad brain region neuron tree sudden fertility disorder. Specifically, a preparation method of a non-human mammal model with the broad brain region neuron tree sudden fertility disorder is provided and comprises the following steps: exposing the non-human mammal to a hypoxia condition for 30-40 minutes so as to obtain an animal model with the broad brain region neuron tree sudden fertility disorder, wherein under the hypoxia condition, the oxygen concentration (volume ratio) is reduced from 10-20% to 1-5%. The animal model can be used for researching the broad brain region neuron tree sudden fertility disorder, and can be used for screening and testing specific drugs.